vs

Side-by-side financial comparison of Beeline Holdings, Inc. (BLNE) and FATE THERAPEUTICS INC (FATE). Click either name above to swap in a different company.

Beeline Holdings, Inc. is the larger business by last-quarter revenue ($1.9M vs $1.4M, roughly 1.4× FATE THERAPEUTICS INC). Beeline Holdings, Inc. produced more free cash flow last quarter ($-21.5M vs $-112.0M). Over the past eight quarters, FATE THERAPEUTICS INC's revenue compounded faster (-15.7% CAGR vs -33.0%).

Beeline or билайн is a mobile network operator brand operating in Russia under PJSC VimpelCom, and in Kazakhstan, Kyrgyzstan and Uzbekistan under VEON Ltd. Beeline is Russia's fourth-largest mobile network operator, and main competitors being MTS, MegaFon and T2.

Insys Therapeutics was an American specialty pharmaceutical company based in Chandler, Arizona in 1990. Its main product was Subsys, a sublingual liquid form of the drug fentanyl. Fentanyl is an extremely fast-acting and powerful opioid used to relieve breakthrough pain in cancer patients, and prescription of fentanyl in the US for such pain usually requires documented failure of more conservative therapies.

BLNE vs FATE — Head-to-Head

Bigger by revenue
BLNE
BLNE
1.4× larger
BLNE
$1.9M
$1.4M
FATE
More free cash flow
BLNE
BLNE
$90.6M more FCF
BLNE
$-21.5M
$-112.0M
FATE
Faster 2-yr revenue CAGR
FATE
FATE
Annualised
FATE
-15.7%
-33.0%
BLNE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BLNE
BLNE
FATE
FATE
Revenue
$1.9M
$1.4M
Net Profit
$-8.4M
Gross Margin
Operating Margin
-418.4%
Net Margin
-445.0%
Revenue YoY
-26.4%
Net Profit YoY
-16.1%
37.9%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BLNE
BLNE
FATE
FATE
Q4 25
$1.9M
$1.4M
Q3 25
$2.3M
$1.7M
Q2 25
$1.7M
$1.9M
Q1 25
$1.8M
$1.6M
Q4 24
$1.9M
Q3 24
$783.0K
$3.1M
Q2 24
$3.1M
$6.8M
Q1 24
$2.5M
$1.9M
Net Profit
BLNE
BLNE
FATE
FATE
Q4 25
$-8.4M
Q3 25
$-3.9M
$-32.3M
Q2 25
$-4.1M
$-34.1M
Q1 25
$-6.8M
$-37.6M
Q4 24
Q3 24
$-1.4M
$-47.7M
Q2 24
$-1.5M
$-38.4M
Q1 24
$-1.3M
$-48.0M
Gross Margin
BLNE
BLNE
FATE
FATE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
25.5%
Q2 24
5.0%
Q1 24
7.5%
Operating Margin
BLNE
BLNE
FATE
FATE
Q4 25
-418.4%
Q3 25
-120.9%
-1995.1%
Q2 25
-229.0%
-1938.5%
Q1 25
-268.7%
-2534.1%
Q4 24
Q3 24
-55.6%
-1703.9%
Q2 24
-11.4%
-665.7%
Q1 24
-18.5%
-2652.9%
Net Margin
BLNE
BLNE
FATE
FATE
Q4 25
-445.0%
Q3 25
-167.2%
-1852.4%
Q2 25
-237.3%
-1786.6%
Q1 25
-372.4%
-2309.5%
Q4 24
Q3 24
-173.6%
-1551.0%
Q2 24
-48.6%
-567.4%
Q1 24
-52.0%
-2493.7%
EPS (diluted)
BLNE
BLNE
FATE
FATE
Q4 25
Q3 25
$-0.20
$-0.27
Q2 25
$-0.64
$-0.29
Q1 25
$-0.32
Q4 24
Q3 24
$-6.60
$-0.40
Q2 24
$-8.74
$-0.33
Q1 24
$-0.78
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BLNE
BLNE
FATE
FATE
Cash + ST InvestmentsLiquidity on hand
$3.1M
$203.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$53.6M
$207.2M
Total Assets
$70.2M
$318.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BLNE
BLNE
FATE
FATE
Q4 25
$3.1M
$203.7M
Q3 25
$1.3M
$215.4M
Q2 25
$6.3M
$222.8M
Q1 25
$1.5M
$240.4M
Q4 24
$279.1M
Q3 24
$310.0K
$296.9M
Q2 24
$420.0K
$304.9M
Q1 24
$147.0K
$121.3M
Total Debt
BLNE
BLNE
FATE
FATE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$8.2M
Q2 24
$8.1M
Q1 24
$8.1M
Stockholders' Equity
BLNE
BLNE
FATE
FATE
Q4 25
$53.6M
$207.2M
Q3 25
$51.7M
$234.1M
Q2 25
$54.6M
$261.4M
Q1 25
$47.1M
$288.4M
Q4 24
$318.7M
Q3 24
$-2.5M
$362.3M
Q2 24
$-1.9M
$397.0M
Q1 24
$-476.0K
$426.1M
Total Assets
BLNE
BLNE
FATE
FATE
Q4 25
$70.2M
$318.9M
Q3 25
$63.2M
$343.7M
Q2 25
$68.6M
$371.6M
Q1 25
$63.8M
$398.7M
Q4 24
$440.7M
Q3 24
$16.2M
$495.0M
Q2 24
$16.6M
$528.8M
Q1 24
$17.0M
$569.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BLNE
BLNE
FATE
FATE
Operating Cash FlowLast quarter
$-21.4M
$-106.1M
Free Cash FlowOCF − Capex
$-21.5M
$-112.0M
FCF MarginFCF / Revenue
-1143.3%
-8183.9%
Capex IntensityCapex / Revenue
0.8%
434.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-199.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BLNE
BLNE
FATE
FATE
Q4 25
$-21.4M
$-106.1M
Q3 25
$-5.8M
$-24.4M
Q2 25
$-4.1M
$-24.6M
Q1 25
$-1.5M
$-33.8M
Q4 24
$-122.9M
Q3 24
$-652.0K
$-29.4M
Q2 24
$-872.0K
$-32.3M
Q1 24
$-82.0K
$-33.4M
Free Cash Flow
BLNE
BLNE
FATE
FATE
Q4 25
$-21.5M
$-112.0M
Q3 25
$-26.6M
Q2 25
$-25.9M
Q1 25
$-35.0M
Q4 24
$-123.6M
Q3 24
$-29.9M
Q2 24
$-32.4M
Q1 24
$-33.4M
FCF Margin
BLNE
BLNE
FATE
FATE
Q4 25
-1143.3%
-8183.9%
Q3 25
-1526.5%
Q2 25
-1360.7%
Q1 25
-2148.9%
Q4 24
-6645.4%
Q3 24
-973.1%
Q2 24
-477.8%
Q1 24
-1736.9%
Capex Intensity
BLNE
BLNE
FATE
FATE
Q4 25
0.8%
434.8%
Q3 25
126.5%
Q2 25
71.4%
Q1 25
73.4%
Q4 24
39.2%
Q3 24
16.1%
Q2 24
0.8%
Q1 24
4.5%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BLNE
BLNE

Beeline Title Holdings$1.4M73%
Other$498.0K27%

FATE
FATE

Segment breakdown not available.

Related Comparisons